A CLINICAL STUDY TO ASSESS THE EFFICACY OF SHWASAHARA DASHEMANI GHANAVATI IN CARDIAC ASTHMA W.S.R L.V.F

Introduction: Shwasa is said as Shigrapranahara Roga. It occurs as the main disease and also a symptom in various diseases. Shwasakruchrata is a common symptom that occurs in Hrudroga. Acharya Charaka mentioned the unique classification of drugs based on their action. Shwasahara Dashemani is one among them. It is containing 10 herbal drugs which are specially indicated in Shwasa Roga. Hence to evaluate the efficacy of Shwasahara Dashemani in Lakshana Roopi Shwasa in L.V.F (Cardiac Asthma) has taken for the study. Aim and Objective: The objective is to assess the efficacy of Shwasahara Dashemani in L.V.F with dyspnea (Cardiac Asthma). Method: The present study is a controlled comparative, open-label, clinical trial with pre and post-test design. A total of 40 subjects of a diagnosed case of L.V.F with dyspnea (Cardiac Asthma) were selected by using a simple random sampling method. Control group subjects were intervened with standard treatment of L.V.F and intervention group subjects were intervened with standard treatment of L.V.F along with Shwasahara Dashemani Ghana Vati, for the duration of 30 days. Its efficacy was assessed before treatment (0th day) and after treatment (31st day) by using BDI (Baseline Dyspnea Index Scale). Results: The P-value of dyspnea of the control group is 1.000 and the P-value of dyspnea of the intervention group is 0.105. This shows that the results of both groups are statistically not significant. But as compared to the control group, the intervention group is clinically significant because after the intervention 35% of subjects had shown improvement in the intervention group. Conclusion: As compared to the control group, in the intervention group Shwasahara Dashemani Ghanavati is clinically significant in relieving cardiac asthma when used with standard treatment of L.V.F. Keyword: Shwasahara Dashemani. Cardiac Asthma, L.V.F, Dyspnea

How to differentiate cardiac asthma from other asthmatic seizures and what treatment to use

Prof. I. Donath (Dio Arztrliche Praxis, No. 5, 1929. Medizinisches Seminar) notes cases of the possibility of an easy delimitation of cardiac or pulmonary asthma from other types of suffocation, and at the same time cases where it is very difficult to make such a delimitation, as, for example, in old people-emphysematics with chronic bronchitis and a weak heart who have shortness of breath as a result of both heart and lung disease. In these latter cases, anti-broncho-asthmatic agents (astmolysin, lysostmin, belladonna and iodine) are successfully used simultaneously with cardiac ones. For pure cardiac asthma, morphine and its derivatives remain the best remedy. Since in some cases it is impossible to establish the absence of a pulmonary component in the etiology of this asthma, and morphine is contraindicated in pure pulmonary asthma, morphine should always be given in combination with caffeine or cardiazole. In many cases, seizures are stopped by injections of pituitrin, pituisan or pituglandol in an amount of 0.5 to 1.0 cm3, as well as nitrites, theobromine, and teominal. Cases of cardiac asthma, leading to symptoms of heart failure and pulmonary edema, are subject to cardiodiuretic therapy, and the best and fastest way is intravenous administration of digipurate in combination with aminophylline or salirgan.

TRADITIONAL USES, PHYTOCHEMISTRY AND PHARMACOLOGICAL ACTIVITIES OF PAPAVER SOMNIFERUM WITH SPECIAL REFERENCE OF UNANI MEDICINE AN UPDATED REVIEW

Papaver somniferum commonly known as Khashkhash /Afyon, belongs to family Papaveraceae. It is one of those traditional plants, which have a long history of usage as medicine. The opium poppy (Papaver somniferum) produces some of the most widely used medicinal alkaloids like morphine, codeine, thebain and porphyroxine which are the most important component of this plant. Apart from these alkaloids, opium poppy produces approximately eighty alkaloids belonging to various tetrahydrobenzylisoquinolinederived classes. It has been known for over a century that morphinan alkaloids accumulate in the latex of opium poppy. According to Unani literature, it possesses most important theurapeutic values as modern literature and research studies also prove its therapeutical importance. It is used as analgesic, narcotic, sedative, stimulant as well as nutritive, etc. It is also useful in headache, cough, insomnia, cardiac asthma, and biliary colic. In this paper we have provide a review on habitate, pharmacological actions, phytochemical with special refrence to Unani Medicine. In this review, an attempt is made to explore the complete information of Papaver somniferum including its phytochemistry and pharmacology. Key words: Khashkhash, Biliary colic, Alkaloid, phytochemistry.

Cor Triatriatum: A Review

Cor triatriatum is a rare congenital cardiac anomaly defined by an abnormal septation within the atrium (left or right) leading to inflow obstruction to the respective ventricles. It exists either in isolated classical form or may be associated with simple to complex congenital cardiac anomalies. Several anatomical variants exist even in the classical form, and therefore, it may require multimodal diagnostic modalities to characterize and differentiate for better percutaneous interventional or surgical planning. It commonly presents in infancy but may remain undetected till death. Symptomatology typically mimics mitral and tricuspid stenosis in sinister and dexter varieties, respectively. However, features of systemic embolization, heart failure, atrial fibrillation, cyanosis, cardiac asthma, syncope, and sudden cardiac arrest have also been reported in the literature. Surgical correction under cardiopulmonary bypass is the preferred treatment. Nevertheless, balloon dilatation may be considered in anatomically compatible variants and in special circumstances, such as heart failure, pregnancy, or as a bridge to definitive treatment.

Adult Cardiac Conditions

In this chapter, the relationship between asthma and its cardiovascular comorbidities is reviewed. Asthma seems not to be a risk factor for coronary heart disease in middle-aged adults; nevertheless, some reports suggest that subjects with severe asthma, especially females, are at significant risk for ischemic heart disease. Additionally, adult-onset asthma, particularly in females, may be a significant risk factor for coronary heart disease. The physician should know how to differentiate between asthma, chronic obstructive pulmonary disease, and cardiac asthma (congestive heart failure), often a difficult proposition. A systematic evaluation, not only of the presence of comorbid conditions, is necessary to ensure that such comorbidities are adequately treated and controlled so that the effect on asthma is minimized.